CN101385836B - Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof - Google Patents
Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof Download PDFInfo
- Publication number
- CN101385836B CN101385836B CN2007101454092A CN200710145409A CN101385836B CN 101385836 B CN101385836 B CN 101385836B CN 2007101454092 A CN2007101454092 A CN 2007101454092A CN 200710145409 A CN200710145409 A CN 200710145409A CN 101385836 B CN101385836 B CN 101385836B
- Authority
- CN
- China
- Prior art keywords
- dermatomyositis
- chinese medicine
- poria
- medicine composition
- cortex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a Chinese medicine composite containing poria for curing dermatomyositis and a preparation thereof. In the collateral disease theory of traditional Chinese medicine, dermatomyositis is ascribed to 'flaccidity syndrome', the pathogenesis mainly includes deficiency of spleen and kidney, no source of the production and transformation of qi and blood, the incapability of weakened body resistance to inhibit pathogen, and the stagnation of skin channels by chill and dampness and heat, thus further affecting liver, kidney and spleen, causing the stasis of viscera yin collaterals, qi-blood disharmony, as well as malnutrition of the tendons and channels of limb skin. The composite adopts the collateral disease theory of traditional Chinese medicine and aims at such pathogenesis of dermatomyositis as dampness-heat retention in spleen and stagnation of qi and collateral stagnation to determine the treatment based on differentiation of symptoms and signs; the materials of poria, the rhizome of large-headed atractylodes, phellodendron, achyranthes, coixseed, rhizoma coptidis, fructus tsaoko, magnolia officinalis, herba artemisiae capillaris, eupatorium japonicum, balloon flower and safflower are selected and used, thus obtaining the efficacies of invigorating the spleen for removing the dampness, clearing away heat and toxic material, regulating qi and dredging channels. Tested by clinical study, the composite can effectively cure the dermatomyositis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Poria, belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Dermatomyositis (dermatomyositis, DM) be a kind of striped muscle that mainly involves, apyetous inflammatory myopathy based on lymphocytic infiltration, belong to one of autoimmunity connective tissue disease, the primary disease course of disease is long, the disability rate height is difficult to radical cure, and doctor trained in Western medicine is mainly used glucocorticoid and immunosuppressant treatment.The traditional Chinese medical science is classified as primary disease characteristic symptom and the major lesions mechanism that " myopathy " more meets primary disease.
The dermatomyositis pathogenesis is mainly deficiency of spleen and stomach, and no resource of generating and transforming QI and blood weakened body resistancely can not be driven heresy, and wind and cold is damp and hot to accumulate the network that hinders skin, and then influences the Liver and kidney spleen, causes the internal organs yin collaterals stasis of blood and stagnates, and is qi-blood disharmony, and limbs skin muscle arteries and veins loses supports.The primary disease exopathogen is based on wet, and dampneee being viscous and lingering easily checks mechanism of qi, the humidity hysteresis stagnation of QI, muscle skin meridians impatency is obstructed, its form of expression can have difference, the wet or heat of holding concurrently, or the damp and hot poison that accumulates, or cold-damp go in heat-transformation; Interior-deficiency head blames in the spleen kidney, sees with the deficiency of YIN more, or is the natural endowment deficiency, and cloudy liquid is plain to be lost, or the labor desire is excessively, the smart damage of cloudy consumption, or diseases caused by exogenous pathogenic factor are damp and hot, consumption impairment of QI the moon.The course of disease with the passing of time, deficiency of YIN affecting YANG can be seen syndrome of yang deficiency of spleen and kidney again and wait; No matter invade in the exopathogen, it is puckery still to seek the deficiency of YIN, and no matter sick pathogenic heat noxious dampness is just violated network, still pathogen usually intruding into collateral in protracted disease, and venation is a basic pathology mechanism of dermatomyositis for disease, also is to cause primary disease to show effect repeatedly, delays the principal element that difficulty heals.The clinical manifestation of dermatomyositis: muscle weakness, involve extremity more, can involve cervical region and oblongata myasthenia, even muscle weakness can appear breathing in severe patient; Can accompany skin turgor, or erythema or erythema; Part patient's myalgia.The limb muscle atrophy can appear in late period, and tendon reflex disappears, and severe patient can cause pulmonary fibrosis or paralysis of respiratory muscle death.
Damp and hot tired spleen, stagnation of QI network resistance type dermatomyositis, its clinical manifestation is: lassitude of the limbs and weakness, skin swelling, lower limb more so, nose heave giddy, the arthralgia of the extremities and irritability, erythra is purplish red, fever of the body does not move back, indigestion and loss of appetite vomiting and nausea, dysphagia, red tongue, thick, yellow and greasy fur, slippery and rapid pulse or moisten number.Former because: damp and hot tired spleen, hypoactivity of spleen-YANG, so fortuneization mistake department is lassitude of the limbs and weakness, indigestion and loss of appetite vomiting and nausea, dysphagia; Not removing dampness of spleen, the network of damp and hot numbness resistance skin, thus see skin swelling, the arthralgia of the extremities and irritability, lower limb are more so; Damp and hot going up covered clear key, so nose heave dizziness; The damp-heat accumulation skin, so see that erythra is purplish red, fever of the body does not move back.Red tongue, thick, yellow and greasy fur, slippery and rapid pulse or to moisten number average be damp and hot levying.
Modern medicine is used glucocorticoid, immunoglobulin, immunosuppressant and multivitamin treatment more at present, and wherein glucocorticoid is most widely used general, and is cheap.But the glucocorticoid effect lacks specificity, and life-time service produces various untoward reaction to human body.Tradition Chinese medicine dermatomyositis is also had nothing in common with each other, and the rule of treatment differs.
Summary of the invention
The invention provides a kind of Chinese medicine composition and preparation thereof that contains the treatment dermatomyositis of Poria.The common pathogenesis of venation pathological changes of dermatomyositis is that the QI and blood or the resistance of seminal fluid numbness of channels is obstructed, so collateral dredging is total Therapeutic Principle.
Chinese medicine composition of the present invention is selected Poria, the Rhizoma Atractylodis Macrocephalae, Semen Coicis invigorating the spleen for eliminating dampness for use; Cortex Phellodendri, Rhizoma Coptidis heat clearing and damp drying, eliminating fire and detoxication; Radix Achyranthis Bidentatae, Herba Lycopi's activating blood circulation to dissipate blood stasis, the capable water of collateral dredging; Damp and hot is disease, easily checks mechanism of qi, thereby makes ascending or descending movement of vital Qi not normal, and blockage of meridian is not smooth, thus with Fructus Tsaoko, Cortex Magnoliae Officinalis regulating qi and dredging collateral, make mechanism of qi unobstructed, then damp and hot must the change; The Herba Artemisiae Scopariae clearing away heat-damp and promoting diuresis; Radix Platycodonis, Flos Carthami blood circulation promoting regulates qi collateral dredging.
The invention provides a kind of Chinese medicine composition that contains the treatment dermatomyositis of Poria, it is characterized in that being making by the crude drug of following weight portion ratio:
Poria 6-30 Rhizoma Atractylodis Macrocephalae 9-30 Cortex Phellodendri 6-10 Radix Achyranthis Bidentatae 12-15 Semen Coicis 9-30
Rhizoma Coptidis 6-12 Fructus Tsaoko 6-12 Cortex Magnoliae Officinalis 9-15 Herba Artemisiae Scopariae 9-15 Herba Lycopi 9-18
Radix Platycodonis 9-15 Flos Carthami 6-15
Preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Poria 10-20 Rhizoma Atractylodis Macrocephalae 15-25 Cortex Phellodendri 6-10 Radix Achyranthis Bidentatae 12-15 Semen Coicis 15-25
Rhizoma Coptidis 6-12 Fructus Tsaoko 6-12 Cortex Magnoliae Officinalis 9-15 Herba Artemisiae Scopariae 9-15 Herba Lycopi 9-15
Radix Platycodonis 9-15 Flos Carthami 6-15
More preferably, Chinese medicine composition of the present invention is to be made by the crude drug of following weight portion ratio:
Poria 15 Rhizoma Atractylodis Macrocephalaes 20 Cortex Phellodendris 7.5 Radix Achyranthis Bidentataes 12.5 Semen Coiciss 20
Rhizoma Coptidis 7.5 Fructus Tsaokos 7.5 Cortex Magnoliae Officinalis 12.5 Herba Artemisiae Scopariaes 12.5 Herba Lycopi 12.5
Radix Platycodonis 12.5 spends 12.5
Or make by the crude drug of following weight portion ratio:
Poria 6 Rhizoma Atractylodis Macrocephalaes 30 Cortex Phellodendris 6 Radix Achyranthis Bidentataes 15 Semen Coiciss 30
Rhizoma Coptidis 12 Fructus Tsaokos 6 Cortex Magnoliae Officinalis 9 Herba Artemisiae Scopariaes 15 Herba Lycopi 18
Radix Platycodonis 9 Flos Carthamis 6
Or make by the crude drug of following weight portion ratio:
Poria 27.5 Rhizoma Atractylodis Macrocephalaes 10 Cortex Phellodendris 7.5 Radix Achyranthis Bidentataes 12.5 Semen Coiciss 10
Rhizoma Coptidis 10 Fructus Tsaokos 12 Cortex Magnoliae Officinalis 15 Herba Artemisiae Scopariaes 10 Herba Lycopi 10
Radix Platycodonis 15 Flos Carthamis 12.5
Or make by the crude drug of following weight portion ratio:
Poria 16 Rhizoma Atractylodis Macrocephalaes 21 Cortex Phellodendris 8 Radix Achyranthis Bidentataes 13 Semen Coiciss 21
Rhizoma Coptidis 8 Fructus Tsaokos 9 Cortex Magnoliae Officinalis 12 Herba Artemisiae Scopariaes 12 Herba Lycopi 12
Radix Platycodonis 12 Flos Carthamis 11
The preparation formulation of Chinese medicine composition of the present invention is decoction, powder, capsule, tablet, pill or oral liquid.
The dosage form of Chinese medicine composition of the present invention adopts conventional preparation method preparation, and for example, the preparation technology of Fan Biting " pharmacy of Chinese materia medica " (Shanghai Science Press 1997 December the 1st edition) record makes the acceptable regular dosage form of pharmaceutics.
In the application of the present invention, described Chinese medicine composition is a kind of in decoction, powder, capsule, tablet, pill, the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic, substrate etc.Filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc.; Disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc.; Lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc.; Suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc.; Binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc.; Sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc.; Correctives comprises: sweeting agent and various essence; Antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods of acetic acid chloroethene; Substrate comprises: PEG6000, PEG4000, insect wax etc.For making above-mentioned dosage form can realize pharmacy of Chinese materia medica, need when these dosage forms of preparation, to add acceptable other adjuvant of pharmacy (adjuvant of each dosage form record among the Fan Biting " pharmacy of Chinese materia medica ", Shanghai Science Press December in 1997 the 1st edition).
Preferably, the dermatomyositis of traditional Chinese medicine composition for treating of the present invention is damp and hot tired spleen, stagnation of QI network resistance type dermatomyositis.Our because of heavily invigorating the spleen for eliminating dampness, heat-clearing and toxic substances removing, regulating qi and dredging collateral so treat damp and hot tired spleen, stagnation of QI network resistance type dermatomyositis, has better effect.
Be confirmation clinical drug curative effect of the present invention, the decoction that use prepares according to embodiment 1 described method (to call in the following text: medicine of the present invention) carried out following clinical observation:
One, clinical diagnosis standard
Standard formulation with reference to propositions in 1975 such as Bohan
1, main standard:
A, typical dermatosis (the purplish red erythra of eyelid), peripheral vessel expansion and finger are stretched side squama erythema or extremity trunk erythema.
B, muscular strength reduce flesh tenderness and scleroma, slow movement and the obvious amyotrophy of extremity peri position.
Inflammatory cell infiltration, edema are seen in c, flesh biopsy, muscle fiber hyalinosis or cavity necrosis, and the muscle fiber thickness differs, interstitial fibrosis, muscle fiber orthogenesis etc.
D, sero-enzyme GOT, GPT, LDH, aldolase etc. surpass normal value 5%.
The existing of e, electromyography showed myositis (use 17-hydroxy-11-dehydrocorticosterone or spasmolytic etc. and then can influence positive findings).
2, minor criteria
A, calcific deposit.
B, dysphagia.
3, diagnositc decision
Possess 3 in 5 of the main standard, or 2 of main standard add 2 of minor criterias, promptly be diagnosed as dermatomyositis (skin symptom is not polymyositis for a long time).
Main standard have only 1 and (or) 2 times, then possess 1 of 2 of main standard or main standard and add 2 of minor criterias and promptly be diagnosed as dermatomyositis.
Special-shaped: with the polymyositis or the dermatomyositis of malignant tumor.
Except: struvite muscle illness or dermatomyositis that reason is clear and definite.
4, traditional Chinese medical science disease diagnostic criteria:
Damp and hot tired spleen, stagnation of QI network resistance type
Primary symptom: (1) limb muscle atrophy is unable, (2) skin turgor or erythema (3) arthralgia of the extremities and irritability, and fever of the body does not move back
Inferior disease: (1) red tongue, yellow and greasy fur, (2) slippery and rapid pulse or moisten number;
(3) heaviness of the head as if it were tightly bandaged and (or) limbs are sleepy, (4) indigestion and loss of appetite vomiting and nausea
Two of above primary symptoms or more than add two of time diseases or more than be diagnosed as this type.
Two, data and method
1, physical data:
This research is carried out in Hebei Yi Ling hospital, and all cases meet above-mentioned doctor trained in Western medicine criterion.Age excludes this research greater than 65 years old and the organ injury persons such as severe cardiac, liver, kidney (in the inpatient therapeutic process send out survivor except) of occurring together.Medicine group 105 examples of the present invention are inpatient; Male's 18 examples wherein, women's 87 examples; 13～64 years old age, average 41 years old; The course of disease is smaller or equal to 1 year person's 22 example, 1～3 year person's 40 example, and 4～7 years person's 35 examples, more than or equal to 8 years person's 8 examples, wherein 51 examples met the traditional Chinese medical science disease diagnostic criteria of damp and hot tired spleen, the resistance of stagnation of QI network.Matched group 44 examples also are inpatient; Male's 7 examples wherein, women's 37 examples; 12～60 years old age, average 40 years old; The course of disease is smaller or equal to 1 year person's 7 example, 1～3 year person's 20 example, and 4～7 years person's 4 examples, more than or equal to 8 years person's 3 examples, wherein 28 examples met the damp and hot tired spleen of the traditional Chinese medical science, the traditional Chinese medical science disease diagnostic criteria of stagnation of QI network resistance type.Treat preceding two groups of patients at aspect difference not statistically significants such as sex, age, the course of disease, degree of being in a bad way.
2, Therapeutic Method:
2.1 medicine group of the present invention: take medicine of the present invention, 600 milliliters of every days, divide twice decoction being taken warmly sooner or later.Glucocorticoid treatment: prednisone 0.8-1.5 mg/day/kilogram.Be divided into the S1 subgroup with what wherein meet the diagnostic criteria of damp and hot tired spleen, stagnation of QI network resistance traditional Chinese medical science disease, all the other do not meet damp and hot tired spleen, the resistance of stagnation of QI network the diagnostic criteria of traditional Chinese medical science disease be divided into the S2 subgroup, above-mentioned two hypotypes all adopt identical treatment measure.
2.2 matched group: give merely and glucocorticoid treatment, consumption is the same.
3, be 3 months the course of treatment course of treatment.
4, observation index: deflorescence situation, muscular strength, creatine phosphokinase.That observes untoward reaction, relapse rate and hormone simultaneously removes the situation of subtracting smoothly.The muscular strength grade scale is with reference to the grade scale of Britain Medical Res Council.
5, curative effect determinate standard: " the new Chinese medicine clinical research guideline (dermatomyositis) " of Ministry of Public Health promulgation formulated with reference to nineteen ninety-five.
The clinical recovery standard: erythra disappears fully, and the muscle Myodynamia recovery is normal, and it is normal that myocardium enzyme is recovered.
Clinical produce effects standard: the erythra major part disappears, and the muscle muscular strength increases the 2-3 level, and 2 or above measured value descend and surpass 50% in the myocardium enzyme.
Clinical effective standard: erythra partly disappears, and the muscle muscular strength increases the 1-2 level, and myocardium enzyme has 2 or above decline 25-50%.
Clinical invalid standard: erythra does not have minimizing, and muscular strength increases by 1 grade of less than, the myocardium enzyme equal less than 25% that descends.
6, statistical method
Two groups of curative effects relatively adopt rank test, and total effective rate relatively adopts X 2 test.Adopt the SPSS10.0 statistical software, there is statistical significance P＜0.05 for difference; Two subgroup curative effects more also adopt rank test, and there is statistical significance P＜0.05 for difference;
Three, result
1, medication therapy groups of the present invention and matched group curative effect are relatively
Table 1 liang group clinical curative effect analysis (routine number, %)
| Grouping | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate (%) |
| Medicine group of the present invention | 105 | ?6(5.7) | 55(52.4) | 24(22.9) | 20(19.0) | 81.0 |
| Matched group | 44 | ?2(4.5) | 12(27.3) | 14(31.8) | 16(36.4) | 63.6 |
Two groups of general curative effects relatively adopt rank test, p=0.012, so medicine group of the present invention and matched group have marked difference on general curative effect, and the matched group that is better than evident in efficacy of medicine of the present invention; Two groups of total effective rates relatively adopt X 2 test, p=0.024, so there were significant differences on total effective rate in matched group for medicine group of the present invention, the effective percentage of medicine of the present invention is significantly higher than matched group.
2, different TCM Syndrome Type curative effects relatively
The different TCM Syndrome Type efficacy analysis of table 2 (routine number, %)
| Grouping | The example number | Recovery from illness | Produce effects | Effectively | Invalid | Total effective rate (%) |
| The S1 group | 44 | ?4(9.1) | 29(65.9) | 7(15.9) | 4(9.1) | 90.91 |
| The S2 group | 61 | ?2(3.3) | 26(42.6) | 17(27.9) | 16(26.2) | 73.77 |
Two groups of general curative effects relatively adopt rank test, p=0.002, so S1 group has marked difference with the S2 group on general curative effect, medicine of the present invention is for damp and hot tired spleen, non-damp and hot tired spleen, the stagnation of QI network resistance type dermatomyositis of being better than evident in efficacy of stagnation of QI network resistance type dermatomyositis.
Four, conclusion
Chinese medicine composition of the present invention can effectively be treated dermatomyositis, treats damp and hot tired spleen, stagnation of QI network resistance type dermatomyositis, has better effect.
The specific embodiment
Example below in conjunction with the preparation of medicine decoction of the present invention, powder, capsule, tablet, pill, oral liquid illustrates the specific embodiment of the present invention.
Embodiment 1:
The Poria 15 gram Rhizoma Atractylodis Macrocephalaes 20 gram Cortex Phellodendris 7.5 gram Radix Achyranthis Bidentataes 12.5 gram Semen Coiciss 20 grams
Rhizoma Coptidis 7.5 gram Fructus Tsaokos 7.5 gram Cortex Magnoliae Officinalis 12.5 gram Herba Artemisiae Scopariaes 12.5 gram Herba Lycopi 12.5 grams
Radix Platycodonis 12.5 gram Flos Carthamis 12.5 grams
Preparation method: the above-mentioned raw materials medicine, add clear water and soak half an hour for 1 liter, intense fire decocts to boiling, continue slow fire boiling half an hour, filter 300 milliliters of extracting juice, repeat again to decoct once, filter, 300 milliliters of extracting juice merge the medicine juice of twice decoction, mixing, amount to 600 milliliters, promptly get decoction, divide twice decoction being taken warmly sooner or later.
Embodiment 2:
The Poria 6 gram Rhizoma Atractylodis Macrocephalaes 30 gram Cortex Phellodendris 6 gram Radix Achyranthis Bidentataes 15 gram Semen Coiciss 30 grams
Rhizoma Coptidis 12 gram Fructus Tsaokos 6 gram Cortex Magnoliae Officinalis 9 gram Herba Artemisiae Scopariaes 15 gram Herba Lycopi 18 grams
Radix Platycodonis 9 gram Flos Carthamis 6 grams
Preparation method: formulation method is total to the porphyrize foam routinely, makes powder.
Embodiment 3:
The Poria 27.5 gram Rhizoma Atractylodis Macrocephalaes 10 gram Cortex Phellodendris 7.5 gram Radix Achyranthis Bidentataes 12.5 gram Semen Coiciss 10 grams
Rhizoma Coptidis 10 gram Fructus Tsaokos 12 gram Cortex Magnoliae Officinalis 15 gram Herba Artemisiae Scopariaes 10 gram Herba Lycopi 10 grams
Radix Platycodonis 15 gram Flos Carthamis 12.5 grams
Preparation method: formulation method is made capsule routinely.
Embodiment 5:
The Poria 16 gram Rhizoma Atractylodis Macrocephalaes 21 gram Cortex Phellodendris 8 gram Radix Achyranthis Bidentataes 13 gram Semen Coiciss 21 grams
Rhizoma Coptidis 8 gram Fructus Tsaokos 9 gram Cortex Magnoliae Officinalis 12 gram Herba Artemisiae Scopariaes 12 gram Herba Lycopi 12 grams
Radix Platycodonis 12 gram Flos Carthamis 11 grams
Preparation method: formulation method is made tablet routinely.
Embodiment 6:
The Poria 12 gram Rhizoma Atractylodis Macrocephalaes 17 gram Cortex Phellodendris 7 gram Radix Achyranthis Bidentataes 12 gram Semen Coiciss 17 grams
Rhizoma Coptidis 7 gram Fructus Tsaokos 7 gram Cortex Magnoliae Officinalis 10 gram Herba Artemisiae Scopariaes 10 gram Herba Lycopi 10 grams
Radix Platycodonis 10 gram Flos Carthamis 8 grams
Preparation method: formulation method is made pill routinely.
Embodiment 7:
The Poria 18 gram Rhizoma Atractylodis Macrocephalaes 23 gram Cortex Phellodendris 9 gram Radix Achyranthis Bidentataes 14 gram Semen Coiciss 23 grams
Rhizoma Coptidis 10 gram Fructus Tsaokos 10 gram Cortex Magnoliae Officinalis 13 gram Herba Artemisiae Scopariaes 13 gram Herba Lycopi 13 grams
Radix Platycodonis 13 gram Flos Carthamis 6 grams
Preparation method: formulation method is made oral liquid routinely.
Claims (9)
1. Chinese medicine composition that contains the treatment dermatomyositis of Poria is characterized in that being being made by the crude drug of following weight portion ratio:
Poria 6-30 Rhizoma Atractylodis Macrocephalae 9-30 Cortex Phellodendri 6-10 Radix Achyranthis Bidentatae 12-15 Semen Coicis 9-30
Rhizoma Coptidis 6-12 Fructus Tsaoko 6-12 Cortex Magnoliae Officinalis 9-15 Herba Artemisiae Scopariae 9-15 Herba Lycopi 9-18
Radix Platycodonis 9-15 Flos Carthami 6-15
2. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Poria 10-20 Rhizoma Atractylodis Macrocephalae 15-25 Cortex Phellodendri 6-10 Radix Achyranthis Bidentatae 12-15 Semen Coicis 15-25
Rhizoma Coptidis 6-12 Fructus Tsaoko 6-12 Cortex Magnoliae Officinalis 9-15 Herba Artemisiae Scopariae 9-15 Herba Lycopi 9-15
Radix Platycodonis 9-15 Flos Carthami 6-15
3. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Poria 15 Rhizoma Atractylodis Macrocephalaes 20 Cortex Phellodendris 7.5 Radix Achyranthis Bidentataes 12.5 Semen Coiciss 20
Rhizoma Coptidis 7.5 Fructus Tsaokos 7.5 Cortex Magnoliae Officinalis 12.5 Herba Artemisiae Scopariaes 12.5 Herba Lycopi 12.5
Radix Platycodonis 12.5 Flos Carthamis 12.5
4. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Poria 6 Rhizoma Atractylodis Macrocephalaes 30 Cortex Phellodendris 6 Radix Achyranthis Bidentataes 15 Semen Coiciss 30
Rhizoma Coptidis 12 Fructus Tsaokos 6 Cortex Magnoliae Officinalis 9 Herba Artemisiae Scopariaes 15 Herba Lycopi 18
Radix Platycodonis 9 Flos Carthamis 6
5. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Poria 27.5 Rhizoma Atractylodis Macrocephalaes 10 Cortex Phellodendris 7.5 Radix Achyranthis Bidentataes 12.5 Semen Coiciss 10
Rhizoma Coptidis 10 Fructus Tsaokos 12 Cortex Magnoliae Officinalis 15 Herba Artemisiae Scopariaes 10 Herba Lycopi 10
Radix Platycodonis 15 Flos Carthamis 12.5
6. the Chinese medicine composition of treatment dermatomyositis according to claim 1 is characterized in that being being made by the crude drug of following weight portion ratio:
Poria 16 Rhizoma Atractylodis Macrocephalaes 21 Cortex Phellodendris 8 Radix Achyranthis Bidentataes 13 Semen Coiciss 21
Rhizoma Coptidis 8 Fructus Tsaokos 9 Cortex Magnoliae Officinalis 12 Herba Artemisiae Scopariaes 12 Herba Lycopi 12
Radix Platycodonis 12 Flos Carthamis 11
7. according to the arbitrary described Chinese medicine composition of claim 1-6, the preparation formulation that it is characterized in that this Chinese medicine composition is decoction, powder, capsule, tablet, pill or oral liquid.
8. various preparations as claimed in claim 7 is characterized in that containing one or more pharmaceutically acceptable excipient.
9. according to the arbitrary described dermatomyositis of claim 1-6, it is characterized in that this dermatomyositis is damp and hot tired spleen, stagnation of QI network resistance type dermatomyositis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101454092A CN101385836B (en) | 2007-09-11 | 2007-09-11 | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101454092A CN101385836B (en) | 2007-09-11 | 2007-09-11 | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101385836A CN101385836A (en) | 2009-03-18 |
| CN101385836B true CN101385836B (en) | 2011-08-17 |
Family
ID=40475642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101454092A Active CN101385836B (en) | 2007-09-11 | 2007-09-11 | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101385836B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105853544A (en) * | 2016-04-15 | 2016-08-17 | 宁波优美科新材料有限公司 | Medicine for treating dermatomyositis |
-
2007
- 2007-09-11 CN CN2007101454092A patent/CN101385836B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 邱志济等.朱良春治疗皮肌炎用药经验和特色选析.《辽宁中医杂志》.2003,第30卷(第10期),782-83. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101385836A (en) | 2009-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101700358A (en) | Medicine for treating acute and chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN102188685B (en) | Externally-applied traditional Chinese medicine powder for treating diarrhea type irritable bowel syndrome and preparation method thereof | |
| CN102423444B (en) | Traditional Chinese medicine preparation for treating rheumatism and internal lesion caused by overexertion and preparation method thereof | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN103127464B (en) | Chinese medicament for treating gallstones | |
| CN102423433A (en) | Traditional Chinese drug mixture for treating psoriasis | |
| CN102579975B (en) | Traditional Chinese medicine mixture for treating psoriasis | |
| CN102327395B (en) | Pharmaceutical composition for treating postpartum persistent lochia and preparation method thereof | |
| CN101385836B (en) | Traditional Chinese medicine composition containing poria cocos for treating dermatomyositis and preparation thereof | |
| CN104587267A (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN104547736A (en) | Medicine for treating goiter | |
| CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN101385810B (en) | Traditional Chinese medicine composition containing chinemys reevesii for treating dermatomyositis and preparation thereof | |
| CN101385812B (en) | Traditional Chinese medicine composition containing epimeddium for treating dermatomyositis and preparation thereof | |
| CN101385805B (en) | Traditional Chinese medicine composition containing cicada-shell for treating dermatomyositis and preparation thereof | |
| CN102579895B (en) | Traditional Chinese medicine composition for treating psoriasis | |
| CN101385820B (en) | Traditional Chinese medicine composition containing ephedra for treating dermatomyositis and preparation thereof | |
| CN103536842A (en) | Mixture for treating psoriasis | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN102228613B (en) | Chinese patent medicine for treating tinea capitis | |
| CN105381260A (en) | Traditional Chinese medicine for treating acquired immune deficiency syndrome and preparation method thereof | |
| CN100444877C (en) | A Chinese medicine for treating cholecystitis | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |